Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart
about
Cardiac cAMP: production, hydrolysis, modulation and detectionTherapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic diseaseTherapeutic potential of PDE modulation in treating heart diseasePriming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafilIncreased afterload induces pathological cardiac hypertrophy: a new in vitro modelRole of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.Advances in targeting cyclic nucleotide phosphodiesterasesCyclic nucleotide signalling in kidney fibrosis.Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.cAMP and Epac in the regulation of tissue fibrosis.5-Lipoxygenase facilitates healing after myocardial infarctionIncrease in cellular cyclic AMP concentrations reverses the profibrogenic phenotype of cardiac myofibroblasts: a novel therapeutic approach for cardiac fibrosis.PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction.Phosphodiesterases and cyclic GMP regulation in heart muscle.Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development.Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic diseaseVinexin-β protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway.The role of Epac in the heart.Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.Improved genetically-encoded, FlincG-type fluorescent biosensors for neural cGMP imaging.Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.Generation and phenotypic characterization of Pde1a mutant mice.Real-time monitoring the spatiotemporal dynamics of intracellular cGMP in vascular smooth muscle cells.PDE2-mediated cAMP hydrolysis accelerates cardiac fibroblast to myofibroblast conversion and is antagonized by exogenous activation of cGMP signaling pathways.Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction.Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats.An update on vinpocetine: New discoveries and clinical implications.Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.Roles of PDE1 in Pathological Cardiac Remodeling and Dysfunction.
P2860
Q26781612-10EBE098-B319-4CCA-92F1-7D58F344E16FQ26827629-0D0B59CE-FBB8-44C1-8711-54540C93F09EQ27005761-50F9D26F-CDF8-4BEF-84F0-587994984126Q28084015-55C88731-2C89-499A-84BE-315848FB8E71Q30528600-4F556EC1-0783-4F48-B9D8-FEAA19BBC858Q30575578-162C7C08-F9F5-49BF-BD59-C797CD00C1B7Q33966155-5463A03F-60FC-4A68-A199-B59D4D5D12D9Q34139490-8B8F1E58-0F5C-4FF8-AAD9-3E0BB9B4154BQ35138860-BC0AC519-FFB7-4C30-A325-EA6B36820F10Q36128551-47E4CECE-4F65-460A-8C74-A2E9CEE70F94Q36159130-D3ECD871-7D1E-42C7-B570-F4DBDBF44F95Q37004832-CD2BB70B-67F3-498C-87D6-F6BC9EFBC41DQ37325619-261E5155-B2A8-4510-884F-6E3673AA3C45Q37417757-E1973035-37AC-4906-B03D-F32C566517E4Q38033089-90630888-7314-4345-B6E3-35F6982F80B3Q38112347-B6700481-2311-48A5-A2C6-626B22E08907Q38202115-EAD82E2C-BE39-4724-886E-C4CE7E9A6AB0Q38317549-7DEDE147-C1D7-4D11-9532-0A5277B45929Q38934306-7883D8BD-17E0-4E7C-997D-8DF4316157B4Q38992600-2B8741E2-82D9-4591-BD02-724A737424D5Q39091633-F9B9BBB2-355B-449E-A5D0-5BAF770D7C88Q40286859-AB3CF34A-F0F0-45D5-912D-CCD179CF6E25Q41153428-FFEE4FF5-2748-4D5B-982E-6FD63FCAE852Q41983620-E2511F85-6F1F-4928-82C7-700B97B5140BQ42454314-1C44BF37-A121-40A1-8384-6695B633A43CQ42515895-62EEC2B0-1F35-4B3B-8BFE-2C2DC7599641Q48370513-8CCFC946-E9CD-403D-B51C-8A1FB23655D3Q49567493-6E029E12-F00F-4C8B-802C-7CA7059F7843Q52656382-A7AC713E-87B4-4A0C-932E-F4F784B01927Q52886208-18523E7B-58AF-4E30-920F-9F217A3BDE2DQ55416779-18E6DD8F-7D28-4C1A-9327-77A45884AE67
P2860
Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart
description
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2011
@ast
im November 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2011/11/01)
@sk
vědecký článek publikovaný v roce 2011
@cs
wetenschappelijk artikel (gepubliceerd op 2011/11/01)
@nl
наукова стаття, опублікована в листопаді 2011
@uk
مقالة علمية (نشرت في نوفمبر 2011)
@ar
name
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@ast
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@en
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@nl
type
label
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@ast
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@en
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@nl
prefLabel
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@ast
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@en
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@nl
P2093
P2860
P1476
Cyclic nucleotide phosphodiest ...... matrix remodeling in the heart
@en
P2093
Clint L. Miller
Keigi Fujiwara
Masayoshi Oikawa
Tamlyn Thomas
Wolfgang R. Dostmann
P2860
P2888
P304
P356
10.1007/S00395-011-0228-2
P577
2011-11-01T00:00:00Z
P5875
P6179
1006979184